LENZ Therapeutics, Inc. Stock Price

NasdaqGS:LENZ Community·US$854.5m Market Cap

1 Narratives written by author
1 Comments on narratives written by author
24 Fair Values set on narratives written by author

Create a narrative

LENZ Share Price Performance

US$27.31

-8.42 (-23.57%)

US$200.00

Fair Value

US$27.31

-8.42 (-23.57%)

86.3% undervalued

US$200.00

Fair Value

US$27.31

US$200.00

Wed, 17 Sep 25

Fair ValueUS$200.00

Share Pricen/a

LENZ Community Narratives

MotherHorseEyes·

Fair Value US$200 86.3% undervalued

LENZ Therapeutics - a high risk high reward small cap biotech stock

LENZ Therapeutics

LENZ Therapeutics - a high risk high reward small cap biotech stock

Hello Simply Wallstreet I have some DD on a small cap company I want to share. Firstly I want you all to be aware of the risks associated with small caps.Read more

US$200

86.3% undervalued

MotherHorseEyes Fair Value

Revenue

247.32% p.a.

Profit Margin

15.03%

Future PE

25.02x

Price in 2030

US$277.58

Trending Discussion

Snowflake Analysis

High growth potential with excellent balance sheet.

1 Risk

3 Rewards

View Full Analysis

LENZ Therapeutics, Inc. Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -1.88
: 100.00%
: -336.47%
: 0%

View Full Analysis

About LENZ

Founded: 2013
Employees: n/a
CEO: Evert Schimmelpennink
WebsiteView website: www.lenz-tx.com

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.